A5049502021- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Peptidase Inhibition and Analysis
- Prostate Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Antimicrobial Peptides and Activities
- Escherichia coli research studies
- Ubiquitin and proteasome pathways
- Clostridium difficile and Clostridium perfringens research
- Pregnancy and preeclampsia studies
- Gut microbiota and health
- Gestational Diabetes Research and Management
- Medical Imaging and Pathology Studies
- Hormonal and reproductive studies
- Cancer Research and Treatments
- Birth, Development, and Health
- Salmonella and Campylobacter epidemiology
- S100 Proteins and Annexins
- Antibiotic Resistance in Bacteria
- Platelet Disorders and Treatments
- Acute Kidney Injury Research
- Radiation Therapy and Dosimetry
- RNA Interference and Gene Delivery
Post Graduate Institute of Medical Education and Research
2010-2025
University of California, San Francisco
2021-2024
UCSF Helen Diller Family Comprehensive Cancer Center
2023
University of California System
2023
McGill University
1964
Molecularly targeted radionuclide therapies (TRTs) struggle with balancing efficacy and safety, as current strategies to increase tumor absorption often alter drug pharmacokinetics prolong circulation normal tissue irradiation. Here we report the first covalent protein TRT, which, through reacting target irreversibly, increases radioactive dose without altering drug's pharmacokinetic profile or biodistribution. Through genetic code expansion, engineered a latent bioreactive amino acid into...
Anaemia is a major health problem among woman of reproductive age group, particularly in developing countries. We undertook this study to determine the maternal and perinatal outcome patients with severe anaemia pregnancy, haemoglobin concentration < 7 g/dl. The in-hospital data were analysed for 12 months between January 2007 December 2.15% (n = 96) women found have anaemia. Out these, 18.75% had pre-term premature rupture membranes 5.12% all deliveries pre-term. Hypertensive diseases...
Abstract Purpose: With the improvement in overall survival with 177Lu-PSMA 617, radioligand therapy (RLT) is now a viable option for patients metastatic castration-resistant prostate cancer (mCRPC). However, responses are variable, part due to low PSMA expression 30% of patients. Herein, we evaluated whether cell surface protein CUB domain-containing 1 (CDCP1) can be exploited treat mCRPC RLT, including PSMA-low subsets. Experimental Design: CDCP1 levels were using RNA sequencing from 119...
Despite recent approvals for checkpoint inhibitors and antibody-drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer remains incurable new treatment strategies are urgently needed. CUB domain-containing protein 1 (CDCP1) is a cell surface promising drug target many cancers. This study aimed to determine whether CDCP1 expressed in can be targeted with radiolabeled antibodies.CDCP1 expression was evaluated four datasets (n = 1,047 biopsies). A tissue microarray of primary...
Understanding how the host immune system engages complex pathogens is essential to developing therapeutic strategies overcome their virulence. While granzymes are well understood trigger apoptosis in infected cells or bacteria, less known about mobilizes individual granzyme species vivo combat diverse pathogens. Toward goal of studying function directly vivo, we previously developed a new class radiopharmaceuticals termed "restricted interaction peptides (RIPs)" that detect biochemically...
To evaluate the diagnostic utility of a single vial ready to label with [99m]Tc kit preparation DTPA-bis-methionine (DTPA-bis-MET) for detection primary breast cancer.The conjugate was synthesized by covalently conjugating two molecules methionine DTPA and formulated as lyophilized preparations. Thirty female patients (mean age=47.5±11.8 years; range=21-69 years) radiological/clinical evidence having carcinoma were subjected [99m]Tc-methionine scintigraphy. The whole body (anterior...
Targeted radionuclide therapy (TRT), whereby a tumor-targeted molecule is linked to therapeutic beta- or alpha-emitting radioactive nuclide, promising treatment modality for patients with metastatic cancer, delivering radiation systemically. However, still progress due suboptimal dosing, driven by the large patient-to-patient variability. Therefore, ability continuously monitor real-time dose deposition in tumors and organs at risk provides an additional dimension of information during...
Demonstrating target engagement in vivo is an important milestone drug development, both to establish on target, tissue interactions but also identify potentially undesirable off binding. The glucocorticoid receptor (GR) a long-studied yet vexing that has recently re-emerged as potential druggable driver of many solid tumor types including breast and prostate cancer, several antagonists are currently early phase clinical trials. Since GR ubiquitously expressed normal tissues, understanding...
<div>AbstractPurpose:<p>Despite recent approvals for checkpoint inhibitors and antibody–drug conjugates targeting NECTIN4 or TROP2, metastatic bladder cancer remains incurable new treatment strategies are urgently needed. CUB domain–containing protein 1 (CDCP1) is a cell surface promising drug target many cancers. This study aimed to determine whether CDCP1 expressed in can be targeted with radiolabeled antibodies.</p>Experimental Design:<p><i>CDCP1</i>...
<p>CDCP1 mRNA expression by clinical stage in the Seiler dataset. p=0.12 Kruskal-Wallis test.</p>
<p>CDCP1 protein expression by clinical stage using the tissue microarray. p=0.32 Kruskal-Wallis test.</p>